Bitter gourd (Momordica charantia) is a cornucopia of health: A review of its credited antidiabetic, Anti-HIV, and antitumor properties

Current Molecular Medicine

Volumn 11, Issue 5, 2011, Pages 417-436

  Fang, E F ^a   Ng, T B ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Diabetes; Human immunodeficiency virus; Medicinal application; Momordica charantia; Tumor

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 9,11,13 CONJUGATED LINOLENIC ACID; AGLYCONE; ALPHA MOMORCHARIN; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BETA MOMORCHARIN; CHARANTIN; FENOFIBRATE; GAMMA MOMORCHARIN; GW 50156; KARAVILOSIDE XI; KUGUACIN 12; KUGUACIN 14; LINOLENIC ACID; MAP 30; MOMORDICA CHARANTIA EXTRACT; MOMORDICOSIDE Q; MOMORDICOSIDE R; MOMORDICOSIDE S; MOMORDICOSIDE T; MOMORDIN I A; MOMORDIN II B; PROTEIN MCL; RICIN; ROSIGLITAZONE; TRITERPENE 1; TRITERPENE 2; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIDIABETIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOMODULATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOGENESIS; MOMORDICA CHARANTIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; REVIEW; SYSTEMATIC REVIEW;

ANIMALS; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; DRUGS, CHINESE HERBAL; HIV; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MOMORDICA CHARANTIA;

HUMAN IMMUNODEFICIENCY VIRUS; MOMORDICA CHARANTIA;

EID: 79959293885     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652411795976583     Document Type: Review

References (188)

1. Krawinkel MB, Keding GB. Bitter gourd (Momordica Charantia): A dietary approach to hyperglycemia. Nutr Rev 2006; 64: 331-7.
2. Schaefer H, Renner SS. A three-genome phylogeny of Momordica (Cucurbitaceae) suggests seven returns from dioecy to monoecy and recent long-distance dispersal to Asia. Mol Phylogenet Evol 2010; 54: 553-60.
3. Ng TB, Wong CM, Li WW, Yeung HW. Isolation and characterization of a galactose binding lectin with insulinomimetic activities. From the seeds of the bitter gourd Momordica charantia (Family Cucurbitaceae). Int J Pept Protein Res 1986; 28: 163-72.
4. Li SC. Pen Ts'ao Kang Mu (Chinese Pharmaceutical Compendium) Beijing: People's Medical Publishing House 1596.
5. Grover JK, Yadav SP. Pharmacological actions and potential uses of Momordica charantia: a review. J Ethnopharmacol 2004; 93: 123-32.
6. Yeung HW, Li WW, Feng Z, Barbieri L, Stirpe F. Trichosanthin, alpha-momorcharin and beta-momorcharin: identity of abortifacient and ribosome-inactivating proteins. Int J Pept Protein Res 1988; 31: 265-8.
7. Puri M, Kaur I, Kanwar RK, Gupta RC, Chauhan A, Kanwar JR. Ribosome inactivating proteins (RIPs) from Momordica charantia for anti viral therapy. Curr Mol Med 2009; 9: 1080-94.
8. Huang HL, Hong YW, Wong YH, et al. Bitter melon (Momordica charantia L.) inhibits adipocyte hypertrophy and down regulates lipogenic gene expression in adipose tissue of diet-induced obese rats. Br J Nutr 2008; 99: 230-9.
9. Ng TB, Wong CM, Li WW, Yeung HW. Peptides with antilipolytic and lipogenic activities from seeds of the bitter gourd Momordica charantia (family Cucurbitaceae). Gen Pharmacol 1987; 18: 275-81.
10. Nerurkar PV, Lee YK, Motosue M, Adeli K, Nerurkar VR. Momordica charantia (bitter melon) reduces plasma apolipoprotein B-100 and increases hepatic insulin receptor substrate and phosphoinositide-3 kinase interactions. Br J Nutr 2008; 100: 751-9.
11. Ooi CP, Yassin Z, Hamid TA. Momordica charantia for type 2 diabetes mellitus. Cochrane Database Syst Rev In press; 2: CD007845.
12. Leung L, Birtwhistle R, Kotecha J, Hannah S, Cuthbertson S. Anti-diabetic and hypoglycaemic effects of Momordica charantia (bitter melon): a mini review. Br J Nutr 2009; 102: 1703-8.
13. Stirpe F, Wawrzynczak EJ, Brown AN, et al. Selective cytotoxic activity of immunotoxins composed of a monoclonal anti-Thy 1.1 antibody and the ribosome-inactivating proteins bryodin and momordin. Br J Cancer 1988; 58: 558-61.
14. Singh A, Singh SP, Bamezai R. Momordica charantia (Bitter Gourd) peel, pulp, seed and whole fruit extract inhibits mouse skin papillomagenesis. Toxicol Lett 1998; 94: 37-46.
15. Kohno H, Yasui Y, Suzuki R, Hosokawa M, Miyashita K, Tanaka T. Dietary seed oil rich in conjugated linolenic acid from bitter melon inhibits azoxymethane-induced rat colon carcinogenesis through elevation of colonic PPARgamma expression and alteration of lipid composition. Int J Cancer 2004; 110: 896-901.
16. Wang YX, Neamati N, Jacob J, et al. Solution structure of anti-HIV-1 and anti-tumor protein MAP30: structural insights into its multiple functions. Cell 1999; 99: 433-42.
17. Yuwai KE, Rao KS, Kaluwin C, Jones GP, Rivett DE. Chemical composition of Momordica charantia L. fruits. J Agric Food Chem 1991; 39: 1762-3.
18. Fong WP, Poon YT, Wong TM, et al. A highly efficient procedure for purifying the ribosome-inactivating proteins alpha- and beta-momorcharins from Momordica charantia seeds, N-terminal sequence comparison and establishment of their N-glycosidase activity. Life Sci 1996; 59: 901-9.
19. Braca A, Siciliano T, D'Arrigo M, Germano MP. Chemical composition and antimicrobial activity of Momordica charantia seed essential oil. Fitoterapia 2008; 79: 123-5.
20. Tan MJ, Ye JM, Turner N, et al. Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. Chem Biol 2008; 15: 263-73.
21. Putnam CD, Tainer JA. The food of sweet and bitter fancy. Nat Struct Biol 2000; 7: 17-8.
22. Schreiber CA, Wan L, Sun Y, Lu L, Krey LC, Lee-Huang S. The antiviral agents, MAP30 and GAP31, are not toxic to human spermatozoa and may be useful in preventing the sexual transmission of human immunodeficiency virus type 1. Fertil Steril 1999; 72: 686-90.
23. American-diabetes-association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2007; 30 Suppl 1: S42-7.
24. Hadar E, Hod M. Establishing consensus criteria for the diagnosis of diabetes in pregnancy following the HAPO study. Ann N Y Acad Sci 2010; 1205: 88-93.
25. Hummasti S, Hotamisligil GS. Endoplasmic reticulum stress and inflammation in obesity and diabetes. Circ Res 2010; 107: 579-91.
26. Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001; 345: 790-7.
27. Kahn BB, McGraw TE. Rosiglitazone, PPARgamma, and type 2 diabetes. N Engl J Med 2010; 363: 2667-9.
28. McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med 2010; 363: 2339-50.
29. Johnson RL, Williams SM, Spruill IJ. Genomics, nutrition, obesity, and diabetes. J Nurs Scholarsh 2006; 38: 11-8.
30. Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 2003; 26: 1277-94.
31. Nakamura S, Murakami T, Nakamura J, Kobayashi H, Matsuda H, Yoshikawa M. Structures of new cucurbitanetype triterpenes and glycosides, karavilagenins and karavilosides, from the dried fruit of Momordica charantia L. in Sri Lanka. Chem Pharm Bull (Tokyo) 2006; 54: 1545-50.
32. Popovich DG, Li L, Zhang W. Bitter melon (Momordica charantia) triterpenoid extract reduces preadipocyte viability, lipid accumulation and adiponectin expression in 3T3-L1 cells. Food Chem Toxicol 2010; 48: 1619-26.
33. Han C, Hui Q, Wang Y. Hypoglycaemic activity of saponin fraction extracted from Momordica charantia in PEG/salt aqueous two-phase systems. Nat Prod Res 2008; 22: 1112-9.
34. Chen JC, Liu WQ, Lu L, et al. Kuguacins F-S, cucurbitane triterpenoids from Momordica charantia. Phytochemistry 2009; 70: 133-40.
35. Li QY, Chen HB, Liu ZM, Wang B, Zhao YY. Cucurbitane triterpenoids from Momordica charantia. Magn Reson Chem 2007; 45: 451-6.
36. Akihisa T, Higo N, Tokuda H, et al. Cucurbitane-type triterpenoids from the fruits of Momordica charantia and their cancer chemopreventive effects. J Nat Prod 2007; 70: 1233-9.
37. Baldwa VS, Bhandari CM, Pangaria A, Goyal RK. Clinical trial in patients with diabetes mellitus of an insulin-like compound obtained from plant source. Ups J Med Sci 1977; 82: 39-41.
38. Welihinda J, Karunanayake EH, Sheriff MH, Jayasinghe KS. Effect of Momordica charantia on the glucose tolerance in maturity onset diabetes. J Ethnopharmacol 1986; 17: 277-82.
39. Ahmad N, Hassan MR, Halder H, Bennoor KS. Effect of Momordica charantia (Karolla) extracts on fasting and postprandial serum glucose levels in NIDDM patients. Bangladesh Med Res Counc Bull 1999; 25: 11-3.
40. Khanna P, Jain SC, Panagariya A, Dixit VP. Hypoglycemic activity of polypeptide-p from a plant source. J Nat Prod 1981; 44: 648-55.
41. Fujimoto WY. The importance of insulin resistance in the pathogenesis of type 2 diabetes mellitus. Am J Med 2000; 108 Suppl 6a: 9S-14S.
42. Klomann SD, Mueller AS, Pallauf J, Krawinkel MB. Antidiabetic effects of bitter gourd extracts in insulin-resistant db/db mice. Br J Nutr 2010; 104: 1613-20.
43. Lee CH, Olson P, Hevener A, et al. PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci U S A 2006; 103: 3444-9.
44. Reilly SM, Lee CH. PPAR delta as a therapeutic target in metabolic disease. FEBS Lett 2008; 582: 26-31.
45. Cheng HL, Huang HK, Chang CI, Tsai CP, Chou CH. A cellbased screening identifies compounds from the stem of Momordica charantia that overcome insulin resistance and activate AMP-activated protein kinase. J Agric Food Chem 2008; 56: 6835-43.
46. Jakobsen SN, Hardie DG, Morrice N, Tornqvist HE. 5'-AMPactivated protein kinase phosphorylates IRS-1 on Ser-789 in mouse C2C12 myotubes in response to 5-aminoimidazole-4- carboxamide riboside. J Biol Chem 2001; 276: 46912-6.
47. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310: 1642-6.
48. Sasa M, Inoue I, Shinoda Y, et al. Activating effect of momordin, extract of bitter melon (Momordica Charantia L.), on the promoter of human PPARdelta. J Atheroscler Thromb 2009; 16: 888-92.
49. Sivitz WI, DeSautel SL, Kayano T, Bell GI, Pessin JE. Regulation of glucose transporter messenger RNA in insulindeficient states. Nature 1989; 340: 72-4.
50. Shibib BA, Khan LA, Rahman R. Hypoglycaemic activity of Coccinia indica and Momordica charantia in diabetic rats: depression of the hepatic gluconeogenic enzymes glucose-6- phosphatase and fructose-1,6-bisphosphatase and elevation of both liver and red-cell shunt enzyme glucose-6-phosphate dehydrogenase. Biochem J 1993; 292 (Pt 1): 267-70.
51. Tanaka T, Yamamoto J, Iwasaki S, et al. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci U S A 2003; 100: 15924-9.
52. Dressel U, Allen TL, Pippal JB, Rohde PR, Lau P, Muscat GE. The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol Endocrinol 2003; 17: 2477-93.
53. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996; 137: 354-66.
54. Kimura Y, Minami Y, Tokuda T, Nakajima S, Takagi S, Funatsu G. Primary structures of N-linked oligosaccharides of momordin-a, a ribosome-inactivating protein from Momordica charantia seeds. Agric Biol Chem 1991; 55: 2031-6.
55. Husain J, Tickle IJ, Wood SP. Crystal structure of momordin, a type I ribosome inactivating protein from the seeds of Momordica charantia. FEBS Lett 1994; 342: 154-8.
56. Manabe M, Takenaka R, Nakasa T, Okinaka O. Induction of anti-inflammatory responses by dietary Momordica charantia L. (bitter gourd). Biosci Biotechnol Biochem 2003; 67: 2512-7.
57. Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 2008; 34: 2-11.
58. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
59. Cardellini M, Perego L, D'Adamo M, et al. C-174G polymorphism in the promoter of the interleukin-6 gene is associated with insulin resistance. Diabetes Care 2005; 28: 2007-12.
60. Qi L, van Dam RM, Meigs JB, Manson JE, Hunter D, Hu FB. Genetic variation in IL6 gene and type 2 diabetes: tagging- SNP haplotype analysis in large-scale case-control study and meta-analysis. Hum Mol Genet 2006; 15: 1914-20.
61. Spranger J, Kroke A, Mohlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52: 812-7.
62. Ike K, Uchida Y, Nakamura T, Imai S. Induction of interferongamma (IFN-gamma) and T helper 1 (Th1) immune response by bitter gourd extract. J Vet Med Sci 2005; 67: 521-4.
63. Lii CK, Chen HW, Yun WT, Liu KL. Suppressive effects of wild bitter gourd (Momordica charantia Linn. var. abbreviata ser.) fruit extracts on inflammatory responses in RAW264.7 macrophages. J Ethnopharmacol 2009; 122: 227-33.
64. Babish JG, Pacioretty LM, Bland JS, Minich DM, Hu J, Tripp ML. Antidiabetic screening of commercial botanical products in 3T3-L1 adipocytes and db/db mice. J Med Food 2010; 13: 535-47.
65. Okada Y, Okada M, Sagesaka Y. Screening of dried plant seed extracts for adiponectin production activity and tumor necrosis factor-alpha inhibitory activity on 3T3-L1 adipocytes. Plant Foods Hum Nutr 2010; 65: 225-32.
66. Nagasawa T, Inada Y, Nakano S, et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol 2006; 536: 182-91.
67. Wannamethee SG, Lowe GD, Rumley A, Cherry L, Whincup PH, Sattar N. Adipokines and risk of type 2 diabetes in older men. Diabetes Care 2007; 30: 1200-5.
68. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-70.
69. Iwabu M, Yamauchi T, Okada-Iwabu M, et al. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature 2010; 464: 1313-9.
70. McTernan CL, McTernan PG, Harte AL, Levick PL, Barnett AH, Kumar S. Resistin, central obesity, and type 2 diabetes. Lancet 2002; 359: 46-7.
71. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-6.
72. Roffey BW, Atwal AS, Johns T, Kubow S. Water extracts from Momordica charantia increase glucose uptake and adiponectin secretion in 3T3-L1 adipose cells. J Ethnopharmacol 2007; 112: 77-84.
73. Chan LL, Chen Q, Go AG, Lam EK, Li ET. Reduced adiposity in bitter melon (Momordica charantia)-fed rats is associated with increased lipid oxidative enzyme activities and uncoupling protein expression. J Nutr 2005; 135: 2517-23.
74. Elliott SS, Keim NL, Stern JS, Teff K, Havel PJ. Fructose, weight gain, and the insulin resistance syndrome. Am J Clin Nutr 2002; 76: 911-22.
75. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999; 401: 73-6.
76. Segal KR, Landt M, Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 1996; 45: 988-91.
77. Shih CC, Lin CH, Lin WL, Wu JB. Momordica charantia extract on insulin resistance and the skeletal muscle GLUT4 protein in fructose-fed rats. J Ethnopharmacol 2009; 123: 82-90.
78. Shih CC, Lin CH, Lin WL. Effects of Momordica charantia on insulin resistance and visceral obesity in mice on high-fat diet. Diabetes Res Clin Pract 2008; 81: 134-43.
79. Chen Q, Chan LL, Li ET. Bitter melon (Momordica charantia) reduces adiposity, lowers serum insulin and normalizes glucose tolerance in rats fed a high fat diet. J Nutr 2003; 133: 1088-93.
80. Mahomoodally MF, Gurib-Fakim A, Subratty AH. Effect of exogenous ATP on Momordica charantia Linn. (Cucurbitaceae) induced inhibition of D-glucose, L-tyrosine and fluid transport across rat everted intestinal sacs in vitro. J Ethnopharmacol 2007; 110: 257-63.
81. Ahmed I, Adeghate E, Cummings E, Sharma AK, Singh J. Beneficial effects and mechanism of action of Momordica charantia juice in the treatment of streptozotocin-induced diabetes mellitus in rat. Mol Cell Biochem 2004; 261: 63-70.
82. Leatherdale BA, Panesar RK, Singh G, Atkins TW, Bailey CJ, Bignell AH. Improvement in glucose tolerance due to Momordica charantia (karela). Br Med J (Clin Res Ed) 1981; 282: 1823-4.
83. Matsuur H, Asakawa C, Kurimoto M, Mizutani J. Alphaglucosidase inhibitor from the seeds of balsam pear (Momordica charantia) and the fruit bodies of Grifola frondosa. Biosci Biotechnol Biochem 2002; 66: 1576-8.
84. Rathi SS, Grover JK, Vats V. The effect of Momordica charantia and Mucuna pruriens in experimental diabetes and their effect on key metabolic enzymes involved in carbohydrate metabolism. Phytother Res 2002; 16: 236-43.
85. Oliver WR, Jr., Shenk JL, Snaith MR, et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A 2001; 98: 5306-11.
86. Nerurkar PV, Pearson L, Efird JT, Adeli K, Theriault AG, Nerurkar VR. Microsomal triglyceride transfer protein gene expression and ApoB secretion are inhibited by bitter melon in HepG2 cells. J Nutr 2005; 135: 702-6.
87. Wang YX, Lee CH, Tiep S, et al. Peroxisome-proliferatoractivated receptor delta activates fat metabolism to prevent obesity. Cell 2003; 113: 159-70.
88. Carpentier A, Taghibiglou C, Leung N, et al. Ameliorated hepatic insulin resistance is associated with normalization of microsomal triglyceride transfer protein expression and reduction in very low density lipoprotein assembly and secretion in the fructose-fed hamster. J Biol Chem 2002; 277: 28795-802.
89. Sparks JD, Phung TL, Bolognino M, Sparks CE. Insulinmediated inhibition of apolipoprotein B secretion requires an intracellular trafficking event and phosphatidylinositol 3- kinase activation: studies with brefeldin A and wortmannin in primary cultures of rat hepatocytes. Biochem J 1996; 313 (Pt 2): 567-74.
90. Ng TB, Wong CM, Li WW, Yeung HW. Acid-ethanol extractable compounds from fruits and seeds of the bitter gourd Momordica charantia: effects on lipid metabolism in isolated rat adipocytes. Am J Chin Med 1987; 15: 31-42.
91. Ng TB, Hon WK, Lo LH, Li WW, Yeung HW. Effects of alphamomorcharin, beta-momorcharin and alpha-trichosanthin on lipogenesis and testicular and adrenal steroidogenesis in vitro and plasma-glucose levels in vivo. J Ethnopharmacol 1986; 18: 45-53.
92. Chen Z, Torrens JI, Anand A, Spiegelman BM, Friedman JM. Krox20 stimulates adipogenesis via C/EBPbeta-dependent and -independent mechanisms. Cell Metab 2005; 1: 93-106.
93. Wang W, Huang L, Huang Y, et al. Mediator MED23 links insulin signaling to the adipogenesis transcription cascade. Dev Cell 2009; 16: 764-71.
94. Chen Q, Li ET. Reduced adiposity in bitter melon (Momordica charantia) fed rats is associated with lower tissue triglyceride and higher plasma catecholamines. Br J Nutr 2005; 93: 747-54.
95. Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell 1996; 87: 377-89.
96. Numata T, Suzuki A, Kakuta Y, et al. Crystal structures of the ribonuclease MC1 mutants N71T and N71S in complex with 5'-GMP: structural basis for alterations in substrate specificity. Biochemistry 2003; 42: 5270-8.
97. Fang EF, Lin P, Wong JH, Tsao SW, Ng TB. A lectin with anti-HIV-1 reverse transcriptase, antitumor, and nitric oxide inducing activities from seeds of Phaseolus vulgaris cv. extralong autumn purple bean. J Agric Food Chem 2010; 58: 2221-9.
98. Ng TB, Wong JH, Wang H. Recent progress in research on ribosome inactivating proteins. Curr Protein Pept Sci 11: 37-53.
99. Mak AN, Wong YT, An YJ, et al. Structure-function study of maize ribosome-inactivating protein: implications for the internal inactivation region and the sole glutamate in the active site. Nucleic Acids Res 2007; 35: 6259-67.
100. Ng TB, Wong JH, Wang H. Recent progress in research on ribosome inactivating proteins. Curr Protein Pept Sci 2010; 11: 37-53.
101. Fang EF, Ng TB. Ribonucleases of different origins with a wide spectrum of medicinal applications. Biochim Biophys Acta In press;
102. Lee-Huang S, Huang PL, Nara PL, et al. MAP 30: a new inhibitor of HIV-1 infection and replication. FEBS Lett 1990; 272: 12-8.
103. Lee-Huang S, Huang PL, Chen HC, Bourinbaiar A, Huang HI, Kung HF. Anti-HIV and anti-tumor activities of recombinant MAP30 from bitter melon. Gene 1995; 161: 151-6.
104. Wang YX, Jacob J, Wingfield PT, et al. Anti-HIV and antitumor protein MAP30, a 30 kDa single-strand type-I RIP, shares similar secondary structure and beta-sheet topology with the A chain of ricin, a type-II RIP. Protein Sci 2000; 9: 138-44.
105. Lee-Huang S, Huang PL, Bourinbaiar AS, Chen HC, Kung HF. Inhibition of the integrase of human immunodeficiency virus (HIV) type 1 by anti-HIV plant proteins MAP30 and GAP31. Proc Natl Acad Sci U S A 1995; 92: 8818-22.
106. Huang PL, Sun Y, Chen HC, Kung HF, Lee-Huang S. Proteolytic fragments of anti-HIV and anti-tumor proteins MAP30 and GAP31 are biologically active. Biochem Biophys Res Commun 1999; 262: 615-23.
107. Arazi T, Lee Huang P, Huang PL, et al. Production of antiviral and antitumor proteins MAP30 and GAP31 in cucurbits using the plant virus vector ZYMV-AGII. Biochem Biophys Res Commun 2002; 292: 441-8.
108. Bourinbaiar AS, Lee-Huang S. The activity of plant-derived antiretroviral proteins MAP30 and GAP31 against herpes simplex virus in vitro. Biochem Biophys Res Commun 1996; 219: 923-9.
109. Bourinbaiar AS, Lee-Huang S. Potentiation of anti-HIV activity of anti-inflammatory drugs, dexamethasone and indomethacin, by MAP30, the antiviral agent from bitter melon. Biochem Biophys Res Commun 1995; 208: 779-85.
110. Sun Y, Huang PL, Li JJ, Huang YQ, Zhang L, Lee-Huang S. Anti-HIV agent MAP30 modulates the expression profile of viral and cellular genes for proliferation and apoptosis in AIDS-related lymphoma cells infected with Kaposi's sarcoma-associated virus. Biochem Biophys Res Commun 2001; 287: 983-94.
111. Au TK, Collins RA, Lam TL, Ng TB, Fong WP, Wan DC. The plant ribosome inactivating proteins luffin and saporin are potent inhibitors of HIV-1 integrase. FEBS Lett 2000; 471: 169-72.
112. Irvin JD, Uckun FM. Pokeweed antiviral protein: ribosome inactivation and therapeutic applications. Pharmacol Ther 1992; 55: 279-302.
113. D'Cruz OJ, Uckun FM. Effect of pretreatment of semen with pokeweed antiviral protein on pregnancy outcome in the rabbit model. Fertil Steril 2001; 76: 830-3.
114. Uckun FM, Chelstrom LM, Tuel-Ahlgren L, et al. TXU (anti- CD7)-pokeweed antiviral protein as a potent inhibitor of human immunodeficiency virus. Antimicrob Agents Chemother 1998; 42: 383-8.
115. Uckun FM, Rustamova L, Vassilev AO, Tibbles HE, Petkevich AS. CNS activity of Pokeweed anti-viral protein (PAP) in mice infected with lymphocytic choriomeningitis virus (LCMV). BMC Infect Dis 2005; 5: 9.
116. Virgin HW, Walker BD. Immunology and the elusive AIDS vaccine. Nature 2010; 464: 224-31.
117. Van Oijen MG, Preijers FW. Rationale for the use of immunotoxins in the treatment of HIV-infected humans. J Drug Target 1998; 5: 75-91.
118. Claflin AJ, Vesely DL, Hudson JL, et al. Inhibition of growth and guanylate cyclase activity of an undifferentiated prostate adenocarcinoma by an extract of the balsam pear (Momordica charantia abbreviata). Proc Natl Acad Sci U S A 1978; 75: 989-93.
119. Pitchakarn P, Ogawa K, Suzuki S, et al. Momordica charantia leaf extract suppresses rat prostate cancer progression in vitro and in vivo. Cancer Sci 2010; 101: 2234-40.
120. Agrawal R, Beohar T. Chemopreventive and anticarcinogenic effects of momordica charantia extract. Asian Pac J Cancer Prev 2010; 11: 371-5.
121. Nagasawa H, Watanabe K, Inatomi H. Effects of bitter melon (Momordica charantia l.) or ginger rhizome (Zingiber offifinale rosc) on spontaneous mammary tumorigenesis in SHN mice. Am J Chin Med 2002; 30: 195-205.
122. Jilka C, Strifler B, Fortner GW, Hays EF, Takemoto DJ. In vivo antitumor activity of the bitter melon (Momordica charantia). Cancer Res 1983; 43: 5151-5.
123. Takemoto DJ, Dunford C, Vaughn D, Kramer KJ, Smith A, Powell RG. Guanylate cyclase activity in human leukemic and normal lymphocytes. Enzyme inhibition and cytotoxicity of plant extracts. Enzyme 1982; 27: 179-88.
124. Mazumder T, Gaur N, Surolia A. The physicochemical properties of the galactose-specific lectin from Momordica charantia. Eur J Biochem 1981; 113: 463-70.
125. Barbieri L, Zamboni M, Lorenzoni E, Montanaro L, Sperti S, Stirpe F. Inhibition of protein synthesis in vitro by proteins from the seeds of Momordica charantia (bitter pear melon). Biochem J 1980; 186: 443-52.
126. Chandran T, Sharma A, Vijayan M. Crystallization and preliminary X-ray studies of a galactose-specific lectin from the seeds of bitter gourd (Momordica charantia). Acta Crystallogr Sect F Struct Biol Cryst Commun 2010; 66: 1037-40.
127. Tanaka H, Toyama J, Akashi R. Molecular characterization of a galactose-binding lectin from Momordica charantia seeds and its expression in tobacco cells. Asian journal of plant sciences 2009; 8: 544-50.
128. Kavitha M, Bobbili KB, Swamy MJ. Differential scanning calorimetric and spectroscopic studies on the unfolding of Momordica charantia lectin. Similar modes of thermal and chemical denaturation. Biochimie 2010; 92: 58-64.
129. Kelley LA, Sternberg MJ. Protein structure prediction on the Web: a case study using the Phyre server. Nat Protoc 2009; 4: 363-71.
130. Liu B, Bian HJ, Bao JK. Plant lectins: potential antineoplastic drugs from bench to clinic. Cancer Lett 2010; 287: 1-12.
131. Hartley MR, Lord JM. Cytotoxic ribosome-inactivating lectins from plants. Biochim Biophys Acta 2004; 1701: 1-14.
132. Lee-Huang S, Huang PL, Sun Y, Chen HC, Kung HF, Murphy WJ. Inhibition of MDA-MB-231 human breast tumor xenografts and HER2 expression by anti-tumor agents GAP31 and MAP30. Anticancer Res 2000; 20: 653-9.
133. Fan JM, Luo J, Xu J, et al. Effects of recombinant MAP30 on cell proliferation and apoptosis of human colorectal carcinoma LoVo cells. Mol Biotechnol 2008; 39: 79-86.
134. Zhu G, Huang Q, Qian M, Tang Y. Crystal structure of alphamomorcharin in 80% acetonitrile--water mixture. Biochim Biophys Acta 2001; 1548: 152-8.
135. Tam PP, Chan WY, Yeung HW. Viability of alphamomorcharin- treated mouse blastocysts in the pseudopregnant uterus. J Reprod Fertil 1984; 71: 567-72.
136. Ng TB, Liu WK, Sze SF, Yeung HW. Action of alphamomorcharin, a ribosome inactivating protein, on cultured tumor cell lines. Gen Pharmacol 1994; 25: 75-7.
137. Leung SO, Yeung HW, Leung KN. The immunosuppressive activities of two abortifacient proteins isolated from the seeds of bitter melon (Momordica charantia). Immunopharmacology 1987; 13: 159-71.
138. Chan WY, Ng TB, Yeung HW. beta-Momorcharin, a plant glycoprotein, inhibits synthesis of macromolecules in embryos, splenocytes and tumor cells. Int J Biochem 1992; 24: 1039-46.
139. Bian X, Shen F, Chen Y, Wang B, Deng M, Meng Y. PEGylation of alpha-momorcharin: synthesis and characterization of novel anti-tumor conjugates with therapeutic potential. Biotechnol Lett 2010; 32: 883-90.
140. Yuan YR, He YN, Xiong JP, Xia ZX. Three-dimensional structure of beta-momorcharin at 2.55 A resolution. Acta Crystallogr D Biol Crystallogr 1999; 55: 1144-51.
141. Fukunaga Y, Nishimoto E, Yamashita K, Otosu T, Yamashita S. The partially unfolded state of beta-momorcharin characterized with steady-state and time-resolved fluorescence studies. J Biochem 2007; 141: 9-18.
142. Xiong SD, Yu K, Liu XH, et al. Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells. Int J Cancer 2009; 125: 774-82.
143. Valbonesi P, Barbieri L, Bolognesi A, Bonora E, Polito L, Stirpe F. Preparation of highly purified momordin II without ribonuclease activity. Life Sci 1999; 65: 1485-91.
144. Minami Y, Funatsu G. The complete amino acid sequence of momordin-a, a ribosome-inactivating protein from the seeds of bitter gourd (Momordica charantia). Biosci Biotechnol Biochem 1993; 57: 1141-4.
145. Minami Y, Islam MR, Funatsu G. Chemical modifications of momordin-a and luffin-a, ribosome-inactivating proteins from the seeds of Momordica charantia and Luffa cylindrica: involvement of His140, Tyr165, and Lys231 in the protein synthesis inhibitory activity. Biosci Biotechnol Biochem 1998; 62: 959-64.
146. Porro G, Bolognesi A, Caretto P, et al. In vitro and in vivo properties of an anti-CD5-momordin immunotoxin on normal and neoplastic T lymphocytes. Cancer Immunol Immunother 1993; 36: 346-50.
147. Lin JY, Hou MJ, Chen YC. Isolation of toxic and non-toxic lectins from the bitter pear melon Momordica charantia Linn. Toxicon 1978; 16: 653-60.
148. Fang EF, Ng TB. Ribonucleases of different origins with a wide spectrum of medicinal applications. Biochim Biophys Acta-Rev Cancer 2011; 1815: 65-74.
149. Dinota A, Barbieri L, Gobbi M, et al. An immunotoxin containing momordin suitable for bone marrow purging in multiple myeloma patients. Br J Cancer 1989; 60: 315-9.
150. Li M, Chen Y, Liu Z, Shen F, Bian X, Meng Y. Anti-tumor activity and immunological modification of ribosomeinactivating protein (RIP) from Momordica charantia by covalent attachment of polyethylene glycol. Acta Biochim Biophys Sin (Shanghai) 2009; 41: 792-9.
151. Selbo PK, Hogset A, Prasmickaite L, Berg K. Photochemical internalisation: a novel drug delivery system. Tumour Biol 2002; 23: 103-12.
152. Berg K, Selbo PK, Prasmickaite L, et al. Photochemical internalization: a novel technology for delivery of macromolecules into cytosol. Cancer Res 1999; 59: 1180-3.
153. Stirpe F, Olsnes S, Pihl A. Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A. J Biol Chem 1980; 255: 6947-53.
154. Kohno H, Suzuki R, Noguchi R, Hosokawa M, Miyashita K, Tanaka T. Dietary conjugated linolenic acid inhibits azoxymethane-induced colonic aberrant crypt foci in rats. Jpn J Cancer Res 2002; 93: 133-42.
155. Basch E, Gabardi S, Ulbricht C. Bitter melon (Momordica charantia): a review of efficacy and safety. Am J Health Syst Pharm 2003; 60: 356-9.
156. Pu Z, Lu BY, Liu WY, Jin SW. Characterization of the enzymatic mechanism of gamma-momorcharin, a novel ribosome-inactivating protein with lower molecular weight of 11,500 purified from the seeds of bitter gourd (Momordica charantia). Biochem Biophys Res Commun 1996; 229: 287-94.
157. Ide H, Kimura M, Arai M, Funatsu G. The complete amino acid sequence of ribonuclease from the seeds of bitter gourd (Momordica charantia). FEBS Lett 1991; 289: 126.
158. Fong WP, Mock WY, Ng TB. Intrinsic ribonuclease activities in ribonuclease and ribosome-inactivating proteins from the seeds of bitter gourd. Int J Biochem Cell Biol 2000; 32: 571-7.
159. Kimura K, Numata T, Kakuta Y, Kimura M. Amino acids conserved at the C-terminal half of the ribonuclease T2 family contribute to protein stability of the enzymes. Biosci Biotechnol Biochem 2004; 68: 1748-57.
160. Suzuki A, Yao M, Tanaka I, et al. Crystal structures of the ribonuclease MC1 from bitter gourd seeds, complexed with 2'-UMP or 3'-UMP, reveal structural basis for uridine specificity. Biochem Biophys Res Commun 2000; 275: 572-6.
161. Nakagawa A, Tanaka I, Sakai R, Nakashima T, Funatsu G, Kimura M. Crystal structure of a ribonuclease from the seeds of bitter gourd (Momordica charantia) at 1.75 A resolution. Biochim Biophys Acta 1999; 1433: 253-60.
162. Parkash A, Ng TB, Tso WW. Purification and characterization of charantin, a napin-like ribosomeinactivating peptide from bitter gourd (Momordica charantia) seeds. J Pept Res 2002; 59: 197-202.
163. Neumann GM, Condron R, Polya GM. Purification and sequencing of napin-like protein small and large chains from Momordica charantia and Ricinus communis seeds and determination of sites phosphorylated by plant Ca(2+)- dependent protein kinase. Biochim Biophys Acta 1996; 1298: 223-40.
164. Vashishta A, Sahu T, Sharma A, Choudhary SK, Dixit A. In vitro refolded napin-like protein of Momordica charantia expressed in Escherichia coli displays properties of native napin. Biochim Biophys Acta 2006; 1764: 847-55.
165. Fang EF, Wong JH, Lin P, Ng TB. Biochemical characterization of the RNA-hydrolytic activity of a pumpkin 2S albumin. FEBS Lett 2010; 584: 4089-96.
166. Fang EF, Wong JH, Ng TB. Thermostable Kunitz trypsin inhibitor with cytokine inducing, antitumor and HIV-1 reverse transcriptase inhibitory activities from Korean large black soybeans. J Biosci Bioeng 2010; 109: 211-7.
167. Losso JN. The biochemical and functional food properties of the bowman-birk inhibitor. Crit Rev Food Sci Nutr 2008; 48: 94-118.
168. Drag M, Salvesen GS. Emerging principles in proteasebased drug discovery. Nat Rev Drug Discov 2010; 9: 690-701.
169. Kondo H, Nakanose J, Nakagawa A, Tanaka I, Kimura M, Funatsu G. Crystallization and preliminary X-ray studies of two serine proteinase inhibitors, BGIA and BGIT, from the seeds of bitter gourd. J Struct Biol 1997; 120: 204-6.
170. Zeng FY, Qian RQ, Wang Y. The amino acid sequence of a trypsin inhibitor from the seeds of Momordica charantia Linn. Cucurbitaceae FEBS Lett. 1988; 234: 35-8.
171. Hamato N, Koshiba T, Pham TN, et al. Trypsin and elastase inhibitors from bitter gourd (Momordica charantia LINN.) seeds: purification, amino acid sequences, and inhibitory activities of four new inhibitors. J Biochem 1995; 117: 432-7.
172. Bakare RI, Magbagbeola OA, Akinwande AI, Ebuehi OA. Effect of aqueous leaf extract of Momordica charantia on intestinal enzyme activities in diarrhoeagenic mice. Nig Q J Hosp Med 2010; 20: 24-8.
173. Ono T, Tsuji T, Sakai M, et al. Induction of hepatocyte growth factor production in human dermal fibroblasts and their proliferation by the extract of bitter melon pulp. Cytokine 2009; 46: 119-26.
174. Tsai TY, Chu LH, Lee CL, Pan TM. Atherosclerosispreventing activity of lactic acid bacteria-fermented milksoymilk supplemented with Momordica charantia. J Agric Food Chem 2009; 57: 2065-71.
175. Sonibare MA, Moody JO, Adesanya EO. Use of medicinal plants for the treatment of measles in Nigeria. J Ethnopharmacol 2009; 122: 268-72.
176. Parikh BA, Tortora A, Li XP, Tumer NE. Ricin inhibits activation of the unfolded protein response by preventing splicing of the HAC1 mRNA. J Biol Chem 2008; 283: 6145-53.
177. Tseng YL, Liu JJ, Hong RL. Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study. Mol Pharmacol 2002; 62: 864-72.
178. Temsamani J, Vidal P. The use of cell-penetrating peptides for drug delivery. Drug Discov Today 2004; 9: 1012-9.
179. Seto M, Umemoto N, Saito M, Masuho Y, Hara T, Takahashi T. Monoclonal anti-MM46 antibody:ricin A chain conjugate: in vitro and in vivo antitumor activity. Cancer Res 1982; 42: 5209-15.
180. Hayden EC. The AIDS fight: looking ahead to 2010. Nature 2008; 454: 812.
181. Gotay CC. Cancer prevention: major initiatives and looking into the future. Expert Rev Pharmacoecon Outcomes Res 2010; 10: 143-54.
182. Nerurkar P, Ray RB. Bitter melon: antagonist to cancer. Pharm Res 2010; 27: 1049-53.
183. Nhiem NX, Kiem PV, Minh CV, et al. alpha-Glucosidase inhibition properties of cucurbitane-type triterpene glycosides from the fruits of Momordica charantia. Chem Pharm Bull (Tokyo) 2010; 58: 720-4.
184. Hara S, Makino J, Ikenaka T. Amino acid sequences and disulfide bridges of serine proteinase inhibitors from bitter gourd (Momordica charantia LINN.) seeds. J Biochem 1989; 105: 88-91.
185. Xiong JP, Xia ZX, Zhang L, Ye GJ, Jin SW, Wang Y. Crystallization and preliminary crystallographic study of betamomorcharin. J Mol Biol 1994; 238: 284-5.
186. Ren J, Wang Y, Dong Y, Stuart DI. The N-glycosidase mechanism of ribosome-inactivating proteins implied by crystal structures of alpha-momorcharin. Structure 1994; 2: 7-16.
187. Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem 2004; 25: 1605-12.
188. Zhu Y, Huang Q, Qian M, Jia Y, Tang Y. Crystal structure of the complex formed between bovine beta-trypsin and MCTIA, a trypsin inhibitor of squash family, at 1.8-A resolution. J Protein Chem 1999; 18: 505-9.